Skip to main content
. 2017 Sep 1;7(6):657–664. doi: 10.1016/j.apsb.2017.07.004

Fig. 4.

Fig. 4

The Lineweaver-Burk plots (A) and the second plot of slopes from Lineweaver-Burk plots (B) for icotinib inhibition on NCHN-O-glucuronidation in HLMs; The Lineweaver-Burk plots (C) and the second plot of slopes from Lineweaver-Burk plots (D) for erlotinib inhibition on NCHN-O-glucuronidation in HLMs.